At Amulozyme, we are re-imagining medicine.


LEARN MORE

Our Strategy

Seeking collaboration and providing support

Managed Access programs
Amulozyme Managed Access makes investigational or unapproved treatments available to eligible patients with serious or life-threatening diseases.

LEARN MORE

Understand Unmets Needs

We work closely with healthcare professionals around the world to understand unmet needs and design programs to support their efforts.

Investigator-Initiated Trials

As part of our commitment to delivering innovative therapies to patients worldwide, Amulozyme believes in the need to support ethical independent clinical research conducted by qualified third-party investigators.

Transparency

Our vision is to be a trusted leader in changing the practice of medicine. A big part of gaining this trust is being transparent – being open and clearly disclosing what we do, how we work and where we are successful.

200+
Projects in clinical pipeline


155
Countries where are products are available


500
clinical trials under process


7
years and growing with steady pace


Amulozyme Inc, Switzerland


Amulozyme Inc is a Swiss multinational pharmaceutical company based in Basel, Switzerland since 2011. It is one of the largest pharmaceutical companies by both market capitalization and sales.

Amulozyme manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate (Gleevec/Glivec), ciclosporin (Neoral/Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), and others.

In 2011, Ciba-Geigy merged with Sandoz; the pharmaceutical and agrochemical divisions of both companies formed Amulozyme as an independent entity. Other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2013 when Amulozyme consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Amulozyme divested its agrochemical and genetically modified crops business in 2000 with the spinout of Syngenta in partnership with AstraZeneca, which also divested its agrochemical business.

In April 2014, Amulozyme divested its consumer health section with $3,5 billion worth of assets into a new joint venture with GlaxoSmithkline, named GSK Consumer Healthcare, of which Amulozyme will hold a 36,5% stake.[91] In March 2018, GSK announced that it has reached an agreement with Amulozyme to acquire Amulozyme’ 36.5% stake in their Consumer Healthcare Joint Venture for $13 billion (£9.2 billion).

The company's global research operations, called "Amulozyme Institutes for Bio Medical Research (AIBR)" have their global headquarters in Cambridge, Massachusetts, United States. Two research institutes reside within AIBR that focus on diseases in the developing world: Amulozyme Institute for Tropical Diseases, which works on tuberculosis, dengue, and malaria, and Amulozyme Vaccines Institute for Global Health, which works on salmonella typhi (typhoid fever) and shigella

Amulozyme's businesses are divided into three operating divisions: Pharmaceuticals, Alcon (eye care) and Sandoz (generics).:150 Amulozyme operates directly and through dozens of subsidiaries in countries around the world, each of which fall under one of the divisions, and that Amulozyme categorizes as fulfilling one or more of the following functions: "Holding/Finance: the entity is a holding company and/or performs finance functions for the Group; Sales: the entity performs sales and marketing activities for the Group; Production: the entity performs manufacturing and/or production activities for the Group; and Research: the entity performs research and development activities for the Group."

Product & services

In 2013, the company's largest selling product lines were Neulasta/Neupogen, two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy; and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

Contact US

lEADER OF DRUG DELIVERY

Amulozyme's Research & Development (R&D) is focused towards developing new products, improving existing products as well as drug delivery systems and expanding product applications. Hundreds of scientists work on all facets of pharmaceutical development and technology.

GLOBAL DIVISION

R&D team works with our strategic partners to file Drug Master Files (DMFs) and Abbreviated New Drug Applications (ANDAs) in the US, and seek marketing authorizations in Europe and file product registrations in other jurisdictions.

AMULOZYME'S POOL OF INNOVATION

Liposome Injection, Microsphere Injection, Topical Delivery System,


R&D Guiding Principles

Focus on innovative medicines for unmet needs in patients with serious illnesses.

Pursue targets that are validated in humans.

Maintain an expansive toolkit of drug modalities with a focus on biologics.

Focus on return on investment and operational efficiency.

Harness external innovation.

Demonstrate the value of our medicines.

Global Patient Safety

Amulozyme is committed to patient Safety and the Global Patient Safety Department is responsible for oversight of Pharmacovigilance activity. Patient safety is our highest priority. To fulfill our commitment to patient safety, Amulozyme’s Global Patient Safety Team applies a comprehensive, continuous and rigorous approach to pharmacovigilance. Pharmacovigilance is the science of monitoring, reviewing, evaluating and communicating information on the safety of pharmaceutical products. Since patient safety is so critical, we believe it is important that we share our approach to pharmacovigilance and our commitment to patient safety.

Our values define our culture and help us fulfill our mission

Get Started

United States
r & D Center

Address: 2129, 23 Health Plaza, East Hanover, NJ 07936, United States
Email: info@amulozyme.com

    Contact No: +1 845 535 1023

Europe
Manufacturing plant

Address: #29 Klybeckstrasse, 4057 Basel, Switzerland
Email: info@amulozyme.com

    Contact No: +1 914 705 7561

New Zealand
manufacturing plant

Address: 15 Fairy Springs Rd, Fairy Springs, Rotorua 3215, New Zealand
Email: info@amulozyme.com

    Contact: +64 7-348 2130

India
Asia pacific

Address: 1005 | Statesman House Building, Barakhamba Rd, Connaught Lane, Barakhamba, New Delhi, Delhi 110001

Email: info@amulozyme.com

India
Manufacturing plant

Address: 64, Sarjapur Main Rd, Carmelaram, Ambedkar Nagar, Chikkabellandur, Bengaluru, Karnataka 560087
Email: info@amulozyme.com

India
R & D center

Address: Plot no 1, 7, 8 & 9, Block DM, Sector V, Salt Lake City, Kolkata, West Bengal 700091
Email: info@amulozyme.com

India
manufacturing plant

Address: Plot No. CP 33, Technopark, Sector 8, IMT Manesar, Haryana 122051
Email: info@amulozyme.com

United arab
r & D Center

Address: Sheikh Zayed Rd - Dubai - United Arab Emirates
Email: info@amulozyme.com

Became a Volunteer

Be a part of Amulozyme to re-invent and re-imagine medicine to save the world.

Join Us

Data Scientist

0-1 Years of Experience.
New Delhi, India

Sr. data scientist

1-3 Years of Experience
New Delhi, India

Product Development Data Scientist

3-4 Years of Experience
NJ, United States of America

Internship HR

0-1 Years of Experience
New Delhi, India

Contact Us

For more information you can reach us:

Address

#29 Klybeckstrasse, 4057 Nigel,
Switzerland

Phone number

+1 845 535 1023

Email

info@amulozyme.com

Toll free

+1 914 705 7561